Healthcare -
Medical - Devices - NASDAQ - US
$ 2.9
-0.344 %
$ 103 M
Market Cap
-5.8
P/E
1. INTRINSIC VALUE
Balance Sheet
Monogram Orthopaedics, Inc.
| Current Assets | 16.3 M |
| Cash & Short-Term Investments | 15.7 M |
| Receivables | 0 |
| Other Current Assets | 625 K |
| Non-Current Assets | 1.49 M |
| Long-Term Investments | 0 |
| PP&E | 338 K |
| Other Non-Current Assets | 1.15 M |
| Current Liabilities | 1.54 M |
| Accounts Payable | 1.17 M |
| Short-Term Debt | 276 K |
| Other Current Liabilities | 91 K |
| Non-Current Liabilities | 1.73 M |
| Long-Term Debt | 226 K |
| Other Non-Current Liabilities | 1.5 M |
EFFICIENCY
Earnings Waterfall
Monogram Orthopaedics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 430 K |
| Gross Profit | 0 |
| Operating Expenses | 15.3 M |
| Operating Income | -15.3 M |
| Other Expenses | 1.02 M |
| Net Income | -16.3 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Monogram Orthopaedics, Inc.
| Net Income | -16.3 M |
| Depreciation & Amortization | 430 K |
| Capital Expenditures | -84 K |
| Stock-Based Compensation | 1.17 M |
| Change in Working Capital | -839 K |
| Others | 1.68 M |
| Free Cash Flow | -14.1 M |
Wall Street Analysts Price Targets
Monogram Orthopaedics, Inc.
Wall Street analysts predict an average 1-year price target for MGRM of $5.4 , with forecasts ranging from
a
low of
$5.4 to a high of $5.4 .
MGRM Lowest Price Target
Wall Street Target
5.4 USD
86.21%
MGRM Average Price Target
Wall Street Target
5.4 USD
86.21%
MGRM Highest Price Target
Wall Street Target
5.4 USD
86.21%
4. DIVIDEND
ANALYSIS
MGRM does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Monogram Orthopaedics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Monogram Technologies Inc. (MGRM) Q1 2025 Earnings Call Transcript
Monogram Technologies Inc. (NASDAQ:MGRM ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Larry Holub - Investor Relations Noel Knape - Chief Financial Officer Ben Sexson - Chief Executive Officer Conference Call Participants Jason Wittes - ROTH Capital Tom Kerr - Zacks Larry Holub Good afternoon, everyone, and welcome to the Monogram Technologies First Quarter 2025 Financial Results and Business Update Conference Call. A question-and-answer session will follow the formal presentation.
seekingalpha.com
- 1 month ago
Monogram Technologies Reports First Quarter 2025 Financial Results
Receives FDA Clearance for the mBôs™ TKA System Groundbreaking Trial Set to Deliver one of the World's First Autonomous Saw-Based Robotic TKA Surgeries on Live Patients Management to Host Business Update Conference Call Today at 4:30 p.m. Eastern Time AUSTIN, Texas, May 14, 2025 (GLOBE NEWSWIRE) -- Monogram Technologies Inc. (NASDAQ: MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the first quarter ended March 31, 2025.
globenewswire.com
- 1 month ago
Monogram Technologies to Host First Quarter 2025 Results Conference Call on Wednesday, May 14, 2025 at 4:30 p.m. Eastern Time
AUSTIN, TX / ACCESS Newswire / May 6, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company revolutionizing orthopedic surgery, will hold a conference call webcast on Wednesday, May 14, 2025 at 4:30 p.m. Eastern Time in conjunction with its reported financial results for the first quarter ended March 31, 2025, and to discuss regulatory updates, including its recent FDA 510(k) Clearance for the Monogram mBôsTM TKA System and approval to start clinical trials in India, and key milestones.
accessnewswire.com
- 2 months ago
CORRECTION FROM SOURCE: Monogram Technologies Receives Regulatory Approval to Start Clinical Trials in India
Monogram Granted Regulatory Approval to Import mBôs TKA System for Clinical Investigation Patient Enrollment will Begin Shortly; First Live Patient Surgeries are Anticipated within 90 Business Days Critical Milestone Achieved for Multi-Center Clinical Trial in India with Strategic Partner Shalby Hospitals for the mBȏs TKA System AUSTIN, TX / ACCESS Newswire / April 29, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company revolutionizing orthopedic surgery, today announced it has obtained regulatory approval from India's Central Drugs Standard Control Organization ("CDSCO") to import its mBôs TKA system to conduct a 102-patient, multi-center clinical investigation evaluating the safety and effectiveness of the Monogram TKA System. The study will be conducted in collaboration with Shalby Limited (NSE: SHALBY) ("Shalby"), one of the world's largest orthopedic hospital groups.
accessnewswire.com
- 2 months ago
Monogram Technologies Granted Regulatory Approval to Import mBôs TKA System for Clinical Investigation in India
Patient Enrollment will Begin Shortly; First Live Patient Surgeries are Anticipated within 90 Business Days Critical Milestone Achieved for Multi-Center Clinical Trial in India with Strategic Partner Shalby Hospitals for the mBȏs TKA System AUSTIN, TEXAS / ACCESS Newswire / April 29, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company revolutionizing orthopedic surgery, today announced it has obtained regulatory approval from India's Central Drugs Standard Control Organization ("CDSCO") to import its mBôs TKA system to conduct a 102-patient, multi-center clinical investigation evaluating the safety and effectiveness of the Monogram TKA System. The study will be conducted in collaboration with Shalby Limited (NSE: SHALBY) ("Shalby"), one of the world's largest orthopedic hospital groups.
accessnewswire.com
- 2 months ago
Monogram Technologies Partners with Urvin to Launch an Exclusive, Verified Shareholder Community
AUSTIN, TX / ACCESS Newswire / March 20, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, is pleased to announce its partnership with Urvin, a private, verified message board exclusively for active Monogram shareholders. This platform offers a way for shareholders to communicate directly with each other while providing Monogram with an additional tool to provide important company updates and reach the broadest possible shareholder audience.
accessnewswire.com
- 3 months ago
Monogram Technologies Announces FDA 510(k) Clearance for the Monogram mBôsTM TKA System
Monogram May Market the Monogram mBôs™ TKA System, Subject to the Requirements of the Federal Food, Drug, and Cosmetic Act (the Act). The Company is Preparing for Commercialization and Evaluating Strategies to Support the Adoption of its Robotic-Assisted Technology AUSTIN, TX / ACCESS Newswire / March 17, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Monogram mBôs™ TKA System.
accessnewswire.com
- 3 months ago
Monogram Technologies Inc. (MGRM) Q4 2024 Earnings Call Transcript
Monogram Technologies Inc. (NASDAQ:MGRM ) Q4 2024 Earnings Conference Call March 11, 2025 4:30 PM ET Company Participants Larry Holub - Investor Relations Benjamin Sexson - Chief Executive Officer Noel Knape - Chief Financial Officer Conference Call Participants Jason Wittes - ROTH MKM Tom Kerr - Zacks Small-Cap Research Larry Holub Good afternoon everyone. I'm Larry Holub, Director at MZ North America, and would like to welcome you to the Monogram Technologies fourth quarter and full year 2024 financial results and business update conference call.
seekingalpha.com
- 3 months ago
CORRECTION: Monogram Technologies Reports Full Year 2024 Financial Results
This Press Release is Acting as a Correction to the Financial Tables in the Previous Release Completed all Supplemental Testing and has Submitted its Formal Response to the FDA's Additional Information Request (AIR) Management to Host Business Update Conference Call on Wednesday, March 12, 2025, at 4:30 p.m. Eastern Time AUSTIN, TEXAS / ACCESS Newswire / March 12, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the fourth quarter and year ended December 31, 2024.
accessnewswire.com
- 3 months ago
Monogram Technologies Reports Full Year 2024 Financial Results
Completed all Supplemental Testing and has Submitted its Formal Response to the FDA's Additional Information Request (AIR) Management to Host Business Update Conference Call on Wednesday, March 12, 2025, at 4:30 p.m. Eastern Time AUSTIN, TX / ACCESS Newswire / March 12, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the fourth quarter and year ended December 31, 2024.
accessnewswire.com
- 3 months ago
Monogram Technologies to Participate in the 37th Annual ROTH Conference in California March 16-18, 2025
AUSTIN, TX / ACCESS Newswire / March 5, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced that Chief Executive Officer Ben Sexson and Chief Financial Officer Noel Knape will participate in the 37th Annual ROTH Conference at the Laguna Cliffs Marriott Resort & Spa in Dana Point, CA March 16-18, 2025. Mr. Sexson and Mr.
accessnewswire.com
- 4 months ago
Monogram Technologies to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday, March 12, 2025 at 4:30 p.m. Eastern Time
AUSTIN, TX / ACCESS Newswire / February 27, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will hold a conference call webcast on Wednesday, March 12, 2025 at 4:30 p.m. Eastern Time in conjunction with its reported financial results for the fourth quarter and full fiscal year ended December 31, 2024, and to discuss regulatory updates and key milestones.
accessnewswire.com
- 4 months ago
8. Profile
Summary
Monogram Orthopaedics, Inc. MGRM
COUNTRY
US
INDUSTRY
Medical - Devices
MARKET CAP
$ 103 M
Dividend Yield
0.00%
Description
Monogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable mass personalized optimization of orthopedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Arthroplasty Inc. and changed its name to Monogram Orthopaedics, Inc. in March 2017. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Contact
3913 Todd Lane, Austin, TX, 78744
https://www.monogramorthopedics.com
IPO
Date
May 18, 2023
Employees
27
Officers
Mr. Noel Knape CPA, M.B.A.
Chief Financial Officer
Dr. Kamran Shamaei Ph.D.
Chief Technology Officer
Chris Tyson
Executive Vice President - MZ North America
Dr. Douglas Unis
Founder, Chief Medical Officer & Director
Mr. Benjamin Sexson C.F.A.
Chairman of the Board, President & Chief Executive Officer